生物素酶缺乏
生物素
人口
医学
内科学
生物
内分泌学
新生儿筛查
酶
生物化学
环境卫生
作者
Arezou Asgari,Soghra Rouhi Dehnabeh,Mehryar Zargari,Soghra Khani,Hadi Mozafari,Abdolreza Varasteh,Fatemeh Keyfi,Mina Barzegari,Rayhaneh Hasanzaeh,Shohreh Khatami
出处
期刊:PubMed
日期:2016-11-01
卷期号:19 (11): 774-778
被引量:2
摘要
Biotinidase deficiency (BTD) is an autosomal recessive disorder of biotin metabolism. Biotin is a coenzyme that enhances the action of the four enzymes that play an important role in carbohydrates, amino acid, and fatty acid metabolism. Defects in these pathways cause severe metabolic disorder in the body. In general, biotinidase deficiency can be classified into two levels: partial and profound. The incidence of BTD is 1:40,000 to 1:60,000 births in the world, even though no convincing statistical data on the prevalence of this disorder exist in Iran. In this study, we aimed to set up a test for determining biotinidase activity among the Iranian population and report BTD mutations.The quantitative method for the determination of biotinidase activity was set up in the National Biochemistry Reference Laboratory (NBRL) of Pasteur Institute of Iran in Tehran. To detect mutations in BTD, polymerase chain reaction (PCR) was performed followed by DNA sequencing.The biotinidase activity range values were 3.81 - 8.25 nmol/min/mL. We identified 8 BTD patients out of 47 cases with neurologic signs. We detected two mutations, c.98-104del7ins3 and p.Arg79Cys, in 5 patients with profound BTD, and one p.Asp444His mutation in 3 patients with partial BTD.Infants suffering from BTD seem healthy during their first months of life. At present, the screening program for metabolic disorders such as BTD is in progress. The patients that are BTD deficient benefit from the availability of the tests, and consequently receive the Biotin supplements before being clinically affected.
科研通智能强力驱动
Strongly Powered by AbleSci AI